stockrow
Saturday 7 November 2026
Export MNKD’s income statement to Excel — free account
MannKind Corporation
MNKD Healthcare Biotechnology
MannKind Corporation’s revenue for fiscal 2025 (year ended December 2025) was $349.0 million, up 22.2% from fiscal 2024.
- Revenue
- +24.0%
- EPS
- −333.3%
- Free cash flow
- −267.7%
- Total debt
- +201.8%
Quarter to September 2026, against a year earlier
3.92
0.16
+4.26%
Follow MNKD
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | 3 | 2 | — |
| (9.03%) | 40.60% | 71.36% | 182.90% | ||
| 0.99% | (4.14%) | (7.62%) | (12.29%) | ||
ROIC |
10.29% | 4.05% | 2.36% | 0.00% | |
Return on Tangible Assets |
2.89% | (12.01%) | (23.20%) | (34.27%) | |
Average Days of Receivables |
40.13 | 28.47 | 40.06 | 36.23 | |
Free Cash Flow per Share |
0.04 | 0.04 | (0.06) | (0.24) | |
Free Cash Flow |
13.69 | 13.15 | (18.13) | (78.41) | |
Capital Expenditures |
(4.57) | (6.12) | (10.08) | (12.16) | |
| Other line items | |||||
Cash ROIC |
2.37% | 2.65% | (3.89%) | (132.12%) | |
Accounts Receivable Turnover |
13.91 | 12.65 | 11.19 | 14.15 | |
Accounts Payable Turnover |
11.12 | 8.30 | 9.10 | 0.00 | |
Inventory Turnover |
2.78 | 2.25 | 2.66 | 0.00 | |
Average Days of Payables |
37.49 | 67.02 | 41.60 | 0.00 | |
Days of Inventory on Hand |
146.54 | 204.12 | 167.34 | 0.00 | |
Tax Rate |
3.17 | (0.16) | (0.10) | (0.06) | |
Research and Development Expense of Revenue |
19.01% | 20.11% | 19.53% | 18.67% | |
Selling, General and Administrative Expense of Revenue |
41.30% | 48.01% | 50.78% | 56.17% | |
Share Based Compensation of Revenue |
6.93% | 7.00% | 7.11% | 0.00% | |
Interest Coverage |
1.02 | 0.37 | 0.19 | — | |
Operating CF/Net income |
3.11 | (0.81) | 0.18 | 0.89 | |
Depreciation/Fixed assets |
0.16 | 0.22 | 0.26 | 0.00 | |
Capex/Depreciation |
(0.35) | (0.34) | (0.45) | 0.00 | |
Revenue per Share |
1.14 | 1.17 | 1.27 | 1.29 | |
Operating CF per Share |
0.06 | 0.06 | (0.03) | (0.21) | |
Capex per Share |
(0.01) | (0.02) | (0.03) | (0.04) | |
Capex to Sales |
0.01 | 0.02 | 0.03 | 0.03 |
Columns are period end dates · fundamentals updated 5 Nov 2026